Whole Genome Analyses of a Well-Differentiated Liposarcoma Reveals Novel SYT1 and DDR2 Rearrangements
Year: 2014
Type: article
Abstract: Liposarcoma is the most common soft tissue sarcoma, but little is known about the genomic basis of this disease. Given the low cell content of this tumor type, we utilized flow cytometry to isolate the diploid normal and aneuploid tumor populations from a well-differentiated liposarcoma prior to array comparative genomic hybridization and whole genome sequencing. This work revealed massive highly focal amplifications throughout the aneuploid tumor genome including MDM2, a gene that has previously been found to be amplified in well-differentiated liposarcoma. Structural analysis revealed massive rearrangement of chromosome 12 and 11 gene fusions, some of which may be part of double minute chromosomes commonly present in well-differentiated liposarcoma. We identified a hotspot of genomic instability localized to a region of chromosome 12 that includes a highly conserved, putative L1 retrotransposon element, LOC100507498 which resides within a gene cluster (NAV3, SYT1, PAWR) where 6 of the 11 fusion events occurred. Interestingly, a potential gene fusion was also identified in amplified DDR2, which is a potential therapeutic target of kinase inhibitors such as dastinib, that are not routinely used in the treatment of patients with liposarcoma. Furthermore, 7 somatic, damaging single nucleotide variants have also been identified, including D125N in the PTPRQ protein. In conclusion, this work is the first to report the entire genome of a well-differentiated liposarcoma with novel chromosomal rearrangements associated with amplification of therapeutically targetable genes such as MDM2 and DDR2.
Source: PLoS ONE
Authors: Jan B. Egan, Michael T. Barrett, Mia D. Champion, Sumit Middha, Elizabeth Lenkiewicz, Lisa Evers, Princy Francis, Jessica Schmidt, Chang-Xin Shi, Scott Van Wier, Sandra Badar, Gregory Ahmann, K. Martin Kortuem, Nicole J. Boczek, Rafael Fonseca, David W. Craig, John D. Carpten, Mitesh J. Borad, A. Keith Stewart
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,382
Funders: Mayo Clinic, Damon Runyon Cancer Research Foundation, Amgen, Eli Lilly and Company, Celgene, Mayo Foundation for Medical Education and Research, Georgia Clinical and Translational Science Alliance, National Institutes of Health, National Cancer Institute, National Center for Advancing Translational Sciences
Awards: G219020131, G232829279, G2377389061, G2581418637, G2679961467, G2683585098, G3946522409, G4383762584, G548058468, G6722313334, G7403876421, G755924224, Studies on Monoclonal Gammopathies, G8121131476, Eastern Cooperative Oncology Group Operations Office, G9000085250, G9000319385, Paul Calabresi Program in Clinical/Translational Research at Mayo Clinic
OpenAlex ID: W2010728360
